SCHEMBL5151250

SCHEMBL5151250

O=C(O)Cn1c2ccccc2c2ccc(OCCCOc3ccccc3[N+](=O)[O-])cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
KDM4E B2RXH2 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A1 P00352 3/20 0.47
PKM P14618 1/20 0.47
STAT1 P42224 1/20 0.47
KMT2A Q03164 3/20 0.47
RECQL P46063 2/20 0.47
MEN1 O00255 2/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
PSEN1 P49768 6/20 0.46
PSEN2 P49810 6/20 0.46
APH1B Q8WW43 6/20 0.46
NCSTN Q92542 6/20 0.46
APH1A Q96BI3 6/20 0.46
PSENEN Q9NZ42 6/20 0.46
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5151432 0.97 PSEN1 (0.48) NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5154961 0.88 PSEN1 (0.49) NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5151885 0.84 PSEN1 (0.55) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL5152498 0.84 KDM4E (0.50) KDM4EPKMKMT2AMEN1MAPT
SCHEMBL5317917 0.83 KDM4E (0.60) KDM4EPSEN1PSEN2APH1BNCSTN
SCHEMBL5154848 0.83 PSEN1 (0.50) KDM4EPKMKMT2AMEN1MAPT
SCHEMBL5156083 0.83 KDM4E (0.51) KDM4EMAPTPSEN1PSEN2APH1B
SCHEMBL5316092 0.83 PSEN1 (0.52) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL5156262 0.83 KDM4E (0.51) KDM4EKMT2AMEN1MAPTPSEN1
SCHEMBL5156287 0.83 MCL1 (0.56) KDM4EALDH1A1PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070197524-A1 Fluorenes and carbazoles as ligands of the EP2 receptor BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-08-23 US claimed
US-20070197524-A1 Fluorenes and carbazoles as ligands of the EP2 receptor BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-08-23 US disclosed
US-20070197524-A1 Fluorenes and carbazoles as ligands of the EP2 receptor BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-08-23 US disclosed
WO-2007071456-A1 FLUORENES AND CARBAZOLES AS LIGANDS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197524-A1 Fluorenes and carbazoles as ligands of the EP2 receptor PTGER2, PTGER1, PTGDR2 NPC1 1301/4885RAB9A 2665/4885KDM4E 4330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.